Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | OCX | Common Stock, no par value | Purchase | $3.88M | +1.32M | +26.69% | $2.95 | 6.24M | Oct 2, 2024 | Direct | F1, F3 |
transaction | OCX | Common Stock, no par value | Purchase | $0 | 0 | 0% | $0.00* | 6.24M | Oct 2, 2024 | Footnote | F1, F3 |
holding | OCX | Common Stock, no par value | 157 | Oct 2, 2024 | Direct | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | OCX | Warrant to Purchase Common Stock | 150K | Oct 2, 2024 | Common Stock | 150K | $30.60 | Direct | F1, F4 | |||||
holding | OCX | Warrant to Purchase Common Stock | 150K | Oct 2, 2024 | Common Stock | 150K | $30.60 | Footnote | F1, F4 |
Id | Content |
---|---|
F1 | The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
F2 | These securities are directly owned by Neal C. Bradsher. |
F3 | On October 2, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the "Issuer") pursuant to which Broadwood Partners agreed to acquire 1,315,339 shares of the Issuer's Common Stock, no par value (the "Common Shares"), from the Issuer in a private placement for a total purchase price of $3,877,619.38, or $2.948 per Common Share. |
F4 | These warrants are currently exercisable. |